Back to Rounds

Series C Round

For GlycomineBio

$115.0M Apr 17, 2025
Funding Details

GlycomineBio is a biotechnology startup focused on developing replacement therapies for rare genetic diseases. The company is specifically advancing GLM-101 into a phase IIb study in patients with PMM2CDG, a congenital disorder of glycosylation. This funding round will support the clinical development of GLM-101 and further research into additional therapies for rare genetic disorders. GlycomineBio aims to address significant unmet medical needs in the field of rare diseases, leveraging innovative biotechnological approaches to create effective treatments. The company is committed to improving the quality of life for patients suffering from these debilitating conditions by providing novel therapeutic options. The Series C funding will also enable GlycomineBio to expand its research team and enhance its laboratory capabilities to accelerate the development timeline for its therapies.

Confidence Score
Data extraction confidence: 90%
Participating Investors

No investors recorded for this funding round.

Related Tweets

No tweets found for this funding round.

Other Data Sources
1
Exa Round Data
Apr 21, 2025
Exa Enrichment History
1

Fields Updated
amount stage currency announced_date description
Enrichment Details
Stage
Series C
Amount
115.0
Currency
USD
Announced Date
2025-04-17T20:00:01
Description
GlycomineBio is a biotechnology startup focused on developing replacement therapies for rare genetic diseases, specifically advancing GLM-101 into a phase IIb study in patients with PMM2CDG, a congenital disorder of glycosylation.
Enrichment History
  • {'updated_at': '2025-04-24T20:45:58.794707', 'fields_updated': {'amount': True, 'stage': True, 'currency': True, 'announced_date': True, 'description': True}, 'query_used': 'GlycomineBio Series C funding round investment valuation', 'sources_count': 5}
Source URLs